Guido Kranenburg, Pim A de Jong, Jonas W Bartstra, Suzanne J Lagerweij, Marnix G Lam, Jeannette Ossewaarde-van Norel, Sara Risseeuw, Redmer van Leeuwen, Saskia M Imhof, Harald J Verhaar, Job J de Vries, Riemer H J A Slart, Gert Luurtsema, Annemarie M den Harder, Frank L J Visseren, Willem P Mali, Wilko Spiering
BACKGROUND: In pseudoxanthoma elasticum (PXE), low pyrophosphate levels may cause ectopic mineralization, leading to skin changes, visual impairment, and peripheral arterial disease. OBJECTIVES: The authors hypothesized that etidronate, a pyrophosphate analog, might reduce ectopic mineralization in PXE. METHODS: In the Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial, adults with PXE and leg arterial calcifications (n = 74) were randomly assigned to etidronate or placebo (cyclical 20 mg/kg for 2 weeks every 12 weeks)...
March 13, 2018: Journal of the American College of Cardiology